Characteristics | All | FOXC2 | p-value | ||||
(N = 50) | Low (N = 20) | High (N = 30) | |||||
No. | (%) | No. | (40%) | No. | (60%) | ||
Age (years) |
|
|
|
|
|
|
|
Mean ± SD | 56.23 ± 10.99 |
| 49.91 | ±8.72 | 60.16 | ±10.50 | 0.002 |
Median (Range) | 56 (39 - 87) |
| 45 | (39 - 67) | 60 | (40 - 87) | |
≤55 years | 18 | 36% | 14 | (65.2%) | 4 | (21.6%) | <0.001‡ |
>55 years | 32 | 64% | 6 | (34.8%) | 26 | (78.4%) | |
Pathological type |
|
|
|
|
|
|
|
IDC | 39 | 78% | 14 | (49%) | 25 | (51%) | 0.448‡ |
Other | 11 | 22% | 6 | (36.4%) | 5 | (63.6%) | |
Grade |
|
|
|
|
|
|
|
Grade I | 7 | 14% | 5 | (30.4%) | 2 | (8.1%) | 0.03§ |
Grade II | 13 | 26% | 9 | (39.1%) | 4 | (16.2%) | |
Grade III | 30 | 60% | 6 | (30.4%) | 24 | (75.7%) | |
ER |
|
|
|
|
|
|
|
Negative | 20 | 40% | 2 | (4.2%) | 18 | (95.8%) | 0.009‡ |
Positive | 30 | 60% | 18 | (75%) | 12 | (25%) | |
PR |
|
|
|
|
|
|
|
Negative | 22 | 45% | 2 | (4.2%) | 20 | (80%) | 0.008‡ |
Positive | 28 | 55% | 18 | (75%) | 10 | (20%) | |
HER2/neu |
|
|
|
|
|
|
|
Negative | 30 | 40% | 18 | (77.1%) | 12 | (22.9%) | 0.02‡ |
Positive | 20 | 60% | 2 | (4%) | 18 | (96%) | |
Ki-67 |
|
|
|
|
|
|
|
Negative | 20 | 40% | 15 | (87%) | 5 | (13%) | <0.001‡ |
Positive | 30 | 60% | 5 | (21.6%) | 25 | (78.4%) | |
Molecular type |
|
|
|
|
|
|
|
Luminal A | 25 | 41.7% | 25 | (100%) | 0 | (0%) | <0.001‡ |
Luminal B | 10 | 16.7% | 1 | (10%) | 9 | (90%) | |
HER2 amplified | 15 | 25% | 0 | (0%) | 15 | (100%) | |
Triple-ve | 10 | 16.7% | 2 | (20%) | 8 | (80%) | |
T |
|
|
|
|
|
|
|
T1 | 8 | 16% | 8 | (39.1%) | 0 | (0%) | 0.002§ |
T2 | 10 | 20% | 6 | (26.1%) | 4 | (13.5%) | |
T3 | 22 | 44% | 5 | (34.8%) | 17 | (37.8%0 | |
T4 | 10 | 20% | 1 | (0%) | 9 | (37.8%) | |
N |
|
|
|
|
|
|
|